ArticleFrontiers in medicine2026
Efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin formula for enhanced recovery after coronary artery bypass grafting: a propensity score-matched prospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06961136 (Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the clinical efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin Formula (FZYX) for enhanced recovery after coronary artery bypass grafting (CABG) in patients with Qi-Yin deficiency syndrome. Methods: This prospective cohort study utilized 1:1 propensity score matching (PSM). Matched patients ( Results: Post-intervention, the FZYX group demonstrated significantly lower peak Cr (68.50 vs. 74.50 μmol/L, unadjusted Conclusion: FZYX appears to be a safe and promising adjunctive therapy post-CABG. While the primary endpoint was formally negative, exploratory analyses suggest it may provide target organ protection and stable physical recovery, potentially associated with modulating macrophage/monocyte-driven innate inflammation, promoting adaptive immune reconstitution, and accelerating tissue repair. Clinical trial registration: Identifier NCT06961136, https://clinicaltrials.gov/study/NCT06961136.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.